Pregled bibliografske jedinice broj: 735946
Efficacy and tolerability of fluvoxamine in outpatients with anxiety disorders
Efficacy and tolerability of fluvoxamine in outpatients with anxiety disorders // European Psychiatry Volume 23, Supplement 2, April 2008
Nica, 2008. str. 204-204 (poster, međunarodna recenzija, sažetak, ostalo)
CROSBI ID: 735946 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Efficacy and tolerability of fluvoxamine in outpatients with anxiety disorders
Autori
Lasić, Davor ; Marinović Ćurin, Jasna ; Žuljan Cvitanović, Marija ; Glavina, Trpimir.
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, ostalo
Izvornik
European Psychiatry Volume 23, Supplement 2, April 2008
/ - Nica, 2008, 204-204
Skup
16th Association of European Psychiatrists Congress
Mjesto i datum
Nica, Francuska, 05.04.2008. - 09.04.2008
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
fluvoksamin; anksiozni poremećaji
(fluvoxamine; anxiety disorders)
Sažetak
Prospective, three months study of efficacy and tolerability of fluvoxamine in outpatients with Anxiety disorders. The subjects were the patients older than 18 years of age, previously without therapy of treated with other psychopharmacological treatment, with diagnosis of Anxiety disorders (F40 to F49 according to ICD-10 Classification of Mental Disorder). Clinical efficacy was evaluated with Hamilton Anxiety Rating Scale HAM-A and Clinical Global Impression scales at baseline visit, after one month and after three months of fluvoxamine therapy. Side effects were recorded during the therapy. Aim of the study: Evaluation of the efficacy and tolerability of fluvoxamine in outpatients with Anxiety disorders (F40 to F49 according to ICD-10 Classification of Mental Disorder). Inclusion criteria: Female and male outpatients older than 18 years o age treated in Psychiatry Clinic Clinical Hospital Center Split, previously without therapy or treated with other psychopharmacological treatment, to which one of the following Anxiety disorders (F40 to F49 according to ICD-10 Classification of Mental Disorder) was diagnosed. Exclusion criteria: - Hypersensitivity to fluvoxamine - Pregnancy and lactation - Hepatic or kidney insufficiency - Unstable epilepsy - Discontinuation of the treatment with irreversible monoamine oxidase inhibitors less than 14 days prior introduction of fluvoxamine therapy - Discontinuation of moclobemide therapy less than one day prior introduction of fluvoxamine therapy. Statistical methods: Descriptive statistic was used for the analysis of demographic data and incidence of adverse events. Repeated Measures Analysis of Variance was used for data analysis (Statistical software SPSS). Statistical significance was defined as p≤0, 05.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
KBC Split,
Medicinski fakultet, Split
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- Social Science Citation Index (SSCI)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE